24 Oct 2019 --- Takeda Pharmaceutical Company has acquired an exclusive global license to develop and commercialize a celiac disease therapy developed by COUR Pharmaceutical Development Company. TAK-101 is a biodegradable nanoparticle containing gluten, which teaches the immune system that the antigen is safe. By hiding the allergen in a friendly shell, the nanoparticle acts like a Trojan horse to convince the immune system not to attack it. The acquisition follows promising trials by researchers at Northwestern Medicine, which also hinted that similar technology could be used for peanut allergies and multiple sclerosis (MS), as well as other conditions.
 [700x700].jpg)
